In vitro method for the detection of early-stage liver damage
Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.
1. An in vitro method for the detection of early-stage reversible liver damage caused by liver-damaging drugs or other substances harmful for the liver, said method comprising:
(a) determining an amount of human enzyme carbamoyl phosphate synthase (CPS1) or a fragment thereof having CPS 1 immunoreactivity in a serum or plasma sample of a patient who has been exposed to potentially liver-damaging drugs or potentially hepatotoxic substances;
(b) concomitantly with (a) determining a concentration of at least one of a liver enzyme selected from the group consisting of GOT (glutamate oxalacetate transaminase), GPT (serum glutamate pyruvate transaminase), GLDH (glutamate dehydrogenase), gamma-GT (gamma-glutamyl transpeptidase), sorbitol dehydrogenase, alkaline phosphatase, LT (alanine amino-transferase), AST (aspartate amino-transferase), GDH (glycerol phosphate dehydrogenase), HD (lactate dehydrogenase), cholinesterase, LAP (leucine amino-peptidase), GGPT (glutamyl transpeptidase in said sample;
(c) comparing the amount of CPS1 or fragment thereof in the sample with an amount of CPS1 in healthy individuals; and
(d) concluding that early stage liver damage is present in the patient if the amount of CPS 1 in said sample is elevated above the amount of CPS1 in healthy individuals but the concentration in said sample of a liver enzyme determined in (b) is in the normal range.
2. The method of claim 1 , wherein the amount of CPS 1 is measured at selectable intervals in patients at risk but without manifest liver symptoms.
3. The Method of claim 1 wherein the determination is carried out by an immunodiagnostic assay.
4. The method of claim 3 , wherein the immunodiagnostic assay is a sandwich-type assay selective for human CPS 1.
5. The Method of claim 3 , wherein said assay is designed as an accelerated test or POC test (point-of-care test).
6. The Method of claim 1 wherein the determination of CPS 1 is carried out with an assay which identifies intact CPS 1 and/or fragments thereof.
7. The Method of claim 1 wherein CPS 1 is determined in serum or plasma samples of patients who are being treated with drugs which are selected from nonsteroidal antiinflammatory drugs (NSAIDs), analgesics, anabolic steroids, hormonal contraceptives, antigout agents, statins, inhalational anesthetics, antibiotics, sulfonamides, tuberculostatic agents, antitumor agents, psychotropic drugs, cardiovascular agents, phytopharmaceutical drugs, Paracetamol.